Riskpilot← Back to searchSign inGet full accessBioretec Oy
OYActiveY-tunnus 1474196-9Yrittäjänkulma 5Manufacture of medical and dental instruments and supplies · NACE 3250Est. 199840 employees
Revenue 2024
EUR 4,5M
+11650182% vs 2023
EBITDA margin
-90.6%
-45% vs 2023
Equity ratio
82.3%
Financial strength
Net profit 2024
EUR -4,7M
-12289066% vs 2023
| Revenue | EUR 4,5M | +11650182% |
| EBITDA | EUR -4,1M | -45% |
| Net profit | EUR -4,7M | -12289066% |
| Total assets | EUR 11,8M | +7% |
| Equity | EUR 9,7M | +18% |
| Employees | 40 | — |
Legal name
Bioretec Oy
Y-tunnus number
1474196-9
Legal form
Osakeyhtiö
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
12. kesäkuuta 1998
Share capital
EUR 3 748 592
Employees
40 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on harjoittaa lääketieteellisten tuotteiden valmistusta, tuotekehittelyä ja markkinointia. Toimintaansa varten yhtiö voi omistaa ja hallita kiinteistöjä ja osakkeita.
Address
Yrittäjänkulma 5
Phone
+3580207789500
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 499 | 2 003 | 2 942 | 0 | 4 544 |
| Staff expenses | −1 779 | −2 186 | −2 353 | −2 850 | −3 442 |
| EBITDA | −1 750 | −2 525 | −2 125 | −2 833 | −4 118 |
| Depreciation & amort. | −56 | −72 | −99 | −201 | −148 |
| EBIT | −1 805 | −2 598 | −2 224 | −3 034 | −4 266 |
| Net financials | −333 | −3 350 | −124 | −754 | −404 |
| Profit before tax | −2 139 | −5 947 | −2 347 | −3 788 | −4 670 |
| Tax | −0 | −0 | −0 | −1 | −0 |
| Net profit | −2 139 | −5 947 | −2 347 | −0 | −4 670 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 129 | 8 890 | 3 879 | 11 068 | 11 826 |
| Equity | 3 500 | 6 546 | 2 977 | 8 230 | 9 738 |
| Long-term debt | 82 | 42 | 44 | 671 | 434 |
| Short-term debt | 547 | 2 302 | 858 | 1 756 | 1 302 |
| Total debt | 628 | 2 344 | 902 | 2 427 | 1 737 |
EBITDA margin
-90.6%
This company
15.8%
Market median
-673% vs market
20202024
Equity ratio
82.3%
This company
38.2%
Market median
+115% vs market
20202024
Return on equity
-48.0%
This company
18.4%
Market median
-361% vs market
20202024
Net profit margin
-102.8%
This company
8.1%
Market median
-1369% vs market
20202024
Asset turnover
0.38×
This company
1.12×
Market median
-66% vs market
20202024
Debt / equity
0.21×
This company
0.62×
Market median
+66% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SF Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (6) | ||
AG Chief Executive Officer | Chief Executive Officer | 2024 – 2025 |
TJ Chief Executive Officer | Chief Executive Officer | 2019 – 2024 |
PJ Deputy Member | Deputy Member | 2018 – 2020 |
EI | Audit | 2017 – 2023 |
TJ Chief Executive Officer | Chief Executive Officer | 2016 – 2019 |
JM Confidential Clerk | Confidential Clerk | 2025 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2022 | |
| Chairperson | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2018 | |
| Former (6) | ||
| Board of Directors | 2020 – 2024 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2018 – 2022 | |
| Chairperson | 2018 – 2019 | |
| Board of Directors | 2018 – 2019 | |
| Board of Directors | 2019 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bioretec Oy (this company)
Bioretec GmbH, ItävaltaBioretec Inc., YhdysvallatBoard members of Bioretec Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Alan Glenn Donze | Chief Executive Officer | 0 companies |
| Timo Juhani Lehtonen | Chief Executive Officer | 0 companies |
| Pertti Juhani Viitanen | Deputy Member | 0 companies |
| Erika Ida Maria Grönlund | Audit | 0 companies |
| Sarah Frances van Hellenberg Hubar-Fisher | Chief Executive Officer | 0 companies |
| Tomi Juhani Numminen | Chief Executive Officer | 0 companies |
| Johanna Maarit Salko | Confidential Clerk | 0 companies |
| Pekka Ilmari Simula | Board of Directors | 0 companies |
| Justin Harris Barad | Board of Directors | 0 companies |
| Päivi Helena Malinen | Board of Directors | 0 companies |
| Pertti Olavi Törmälä | Board of Directors | 0 companies |
| Juha Allan Kustaa-Adolf Poutiainen | Chairperson | 0 companies |
| Hans Edvard Rosén | Board of Directors | 0 companies |
| Antti Henrik Alex Vasara | Board of Directors | 0 companies |
| Rabbe Ilari Klemets | Chairperson | 0 companies |
| Nils Göran Pettersson | Board of Directors | 0 companies |
| Heinz Moitzi | Board of Directors | 0 companies |
| Michael Hugh Piccirillo | Board of Directors | 0 companies |